Last reviewed · How we verify
Candin, Intradermal Solution
Candin is a candida albicans antigen preparation that stimulates delayed-type hypersensitivity and cell-mediated immune responses against candida infections.
Candin is a candida albicans antigen preparation that stimulates delayed-type hypersensitivity and cell-mediated immune responses against candida infections. Used for Candida-related conditions (specific indication in Phase 3 development unclear).
At a glance
| Generic name | Candin, Intradermal Solution |
|---|---|
| Sponsor | Nielsen BioSciences, Inc. |
| Drug class | Immunotherapeutic antigen preparation |
| Target | Candida albicans antigens |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Candin contains heat-killed candida albicans organisms administered intradermally to provoke a therapeutic immune response. It is designed to enhance the body's own T-cell mediated immunity against candida, potentially treating or preventing candida-related conditions. The intradermal route allows direct presentation of candida antigens to the immune system.
Approved indications
- Candida-related conditions (specific indication in Phase 3 development unclear)
Common side effects
- Local injection site reaction
- Hypersensitivity reaction
Key clinical trials
- Candin for the Treatment of Common Warts (PHASE3)
- Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (PHASE2)
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants (EARLY_PHASE1)
- Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candin, Intradermal Solution CI brief — competitive landscape report
- Candin, Intradermal Solution updates RSS · CI watch RSS
- Nielsen BioSciences, Inc. portfolio CI